ライフサイエンスコーパス: preventive therapy

1 group (antiretroviral therapy and isoniazid preventive therapy).

2 limited impact may be expected of expanding preventive therapy.

3 evated risk of breast cancer and considering preventive therapy.

4 d by the US Food and Drug Administration for preventive therapy.

5 ients who are at risk of relapse in time for preventive therapy.

6 tion of antiretroviral therapy and isoniazid preventive therapy.

7 ion and strengthening the case for secondary preventive therapy.

8 tial to provide a new dimension to secondary preventive therapy.

9 ibitors varespladib methyl and darapladib as preventive therapy.

10 nd in reference subjects who had received no preventive therapy.

11 communicating risks and supporting intensive preventive therapy.

12 y benefit from early spectacle correction or preventive therapy.

13 may aid in determining prognosis and guiding preventive therapy.

14 tuberculosis transmission and on the use of preventive therapy.

15 irculatory changes as an approach to earlier preventive therapy.

16 reater confidence in the safety of isoniazid preventive therapy.

17 finding and increase uptake of tuberculosis preventive therapy.

18 niazid preventive therapy, and 82% completed preventive therapy.

19 ied granulomas) were offered isoniazid (INH) preventive therapy.

20 rpose in assessing indications for isoniazid preventive therapy.

21 n populations will require widespread use of preventive therapy.

22 offered antiretroviral therapy and isoniazid preventive therapy.

23 hat could potentially have been avoided with preventive therapy.

24 4%) saw a physician, and 105 (84%) initiated preventive therapy.

25 were encouraged but not required to undergo preventive therapy.

26 and their effect on counseling about primary preventive therapy.

27 ening for symptoms, active case finding, and preventive therapy.

28 States to determine the need for curative or preventive therapy.

29 omplications annually, there is no effective preventive therapy.

30 and January 1994 and were offered isoniazid preventive therapy.

31 r their positive skin test were eligible for preventive therapy.

32 o their approach for choosing candidates for preventive therapy.

33 of intensified case finding and tuberculosis preventive therapy.

34 works, including prophylactic, emergency, or preventive therapy.

35 Infected patients were offered preventive therapy.

36 rrences may occur in 30% of patients without preventive therapy.

37 ed, phased-implementation trial of isoniazid preventive therapy.

38 biomarkers that indicate early responses to preventive therapy.

39 of follow-up for those initiating isoniazid preventive therapy.

40 improve targeted, cost-effective delivery of preventive therapy.

41 undergo limited evaluations, and few receive preventive therapy.

42 ) among contacts with LTBI who did not start preventive therapy.

43 not, they were offered 9 months of isoniazid preventive therapy.

44 men were attributing age-related symptoms to preventive therapy.

45 ent TB but with LTBI diagnosis, 45% received preventive therapy.

46 presymptomatic phase, and thus implementing preventive therapies.

47 te may represent novel targets for acute and preventive therapies.

48 managed in terms of risk stratification and preventive therapies.

49 archers hope to better define treatments and preventive therapies.

50 ections may lead to important therapeutic or preventive therapies.

51 risk is important for cost-effective use of preventive therapies.

52 minimize the healthy user bias in studies of preventive therapies.

53 e for risk counseling and the development of preventive therapies.

54 atment trials, and increasing application of preventive therapies.

55 ians and researchers insights into potential preventive therapies.

56 ogression and could provide a target for new preventive therapies.

57 future cardiovascular events despite current preventive therapies.

58 h risk for breast cancer who should consider preventive therapies.

59 f HPVs is critical for developing additional preventive therapies.

60 ht provide a better tool for selecting these preventive therapies.

61 ocedures and the safety and effectiveness of preventive therapies.

62 ronary calcium scores, for more personalized preventive therapies.

63 potential risk factors and to develop novel preventive therapies.

64 the 36 HCWs who started but did not complete preventive therapy, 12 discontinued therapy because of a

65 n group than of the employee group completed preventive therapy (25 of 34 [74%] vs 44 of 91 [48%], re

66 More preventive therapies (283 vs. 74; HR: 4.03 [95% CI: 3.12

67 -nine (66%) of the 105off HCWs who initiated preventive therapy (55% of the 125 total) completed at l

68 9 (50%) fit current guidelines for isoniazid preventive therapy, 84 (20%) we intended to treat comple

69 5-7.8) for empirical group and for isoniazid preventive therapy (95% CI 3.4-7.8); absolute risk diffe

70 For preventive therapy, a number of medications have been st

71 ttributed to treatments, including secondary preventive therapies after myocardial infarction or reva

72 andates adequate attention to cardiovascular preventive therapy after diagnosis of breast cancer.

73 uring influenza season would be an effective preventive therapy against influenza in this high-risk p

74 nfection in Botswana receive daily isoniazid preventive therapy against tuberculosis without obtainin

75 proaches also show promise as both acute and preventive therapies, although further studies are neede

76 ed to modern populations with greater use of preventive therapy, although the magnitude of overestima

77 prioritize active case finding or isoniazid preventive therapy among children exposed to TB.

78 ardial infarction (MI) improves adherence to preventive therapies and reduces clinical events.

79 of US adults with PAD who are not receiving preventive therapies and whether treatment is associated

80 black women less often received appropriate preventive therapy and adequate risk factor control desp

81 provements in current programs with targeted preventive therapy and BCG vaccination programs.

82 and weekly dosing is under investigation for preventive therapy and for the continuation phase of tre

83 r we outline challenges to implementation of preventive therapy and provide pragmatic suggestions for

84 individuals who were eligible for isoniazid preventive therapy and the poor adherence with a complet

85 ovement in the coverage and efficacy of both preventive therapy and treatment, coupled with the BCG v

86 d a medical examination, 91% began isoniazid preventive therapy, and 82% completed preventive therapy

87 terventions, such as vaccination programs or preventive therapy, and could also allow for study of ba

88 Screening, preventive therapy, and surveillance for tuberculosis ar

89 n unsatisfactory because available acute and preventive therapies are either ineffective or poorly to

90 vior, and willingness to submit to long-term preventive therapies are significantly influenced by cul

91 utcomes associated with the long-term use of preventive therapies are subject to the so-called "healt

92 Unfortunately, both preventive therapies are underused in low-income and hig

93 Specific recommendations for preventive therapy are being made, but prospective clini

94 he adverse effects and acceptability of this preventive therapy are largely uncharacterized.

95 Isoniazid preventive therapy as an adjunct to ART prevents tubercu

96 Children were started on preventive therapy as per local guidance: ofloxacin, eth

97 We further advocate for tuberculosis preventive therapy as the core of a renewed worldwide fo

98 erculosis infection, medical evaluation, and preventive therapy, as well as the number of active tube

99 is inappropriate and suggested that the term preventive therapy better represents this feature of man

100 fter surgery remains the mainstay of current preventive therapy, but the potential for other antiplat

101 Acceptance of tuberculosis preventive therapy by HCWs was high in the setting of a

102 ly that antiretroviral therapy and isoniazid preventive therapy can be started safely in people whose

103 educing treatment delay, providing isoniazid preventive therapy continuously to human immunodeficienc

104 The role of co-trimoxazole preventive therapy (CPT) in reducing leading causes of i

105 Cotrimoxazole preventive therapy (CPT) is recommended for all human im

106 trial data, we estimate the degree to which preventive therapies cure latent Mycobacterium tuberculo

107 tuberculosis infection and directly observed preventive therapy (DOPT) in methadone maintenance clini

108 y means of community-based directly observed preventive therapy (DOPT).

109 to provide at least 3 doses of intermittent preventive therapy during pregnancy at each scheduled an

110 and quasi-randomized trials of intermittent preventive therapy during pregnancy with sulfadoxine-pyr

111 earlier age and the known benefits of using preventive therapies for PAD, this is the perfect time t

112 Twice-weekly isoniazid preventive therapy for 6 months or rifampicin and pyrazi

113 active disease treatment, and mass isoniazid preventive therapy for 9 months during 2006-2011 among S

114 enous immunoglobulin (IVIG) was evaluated as preventive therapy for CHB.

115 early diagnosis emphasise the importance of preventive therapy for child contacts of patients with t

116 nts and hard-to-reach groups, and the use of preventive therapy for contacts of cases of infectious m

117 Preventive therapy for HIV-1-seropositive, PPD-positive

118 Standard preventive therapy for inactive pulmonary tuberculosis (

119 nario, a combination of continuous isoniazid preventive therapy for individuals on antiretroviral the

120 Isoniazid preventive therapy for latent tuberculosis (TB) infectio

121 atients with tuberculosis, and screening and preventive therapy for latent tuberculosis infections in

122 duced PVOD in rats and should be tested as a preventive therapy for MMC-induced PVOD in humans.

123 ese findings suggest that expanded access to preventive therapy for older children and young-adult ho

124 96 we evaluated a 4-mo, four-drug regimen of preventive therapy for patients with inactive TB, mostly

125 episodes of injury and may be beneficial as preventive therapy for patients with or at risk of devel

126 4-mo regimen had no advantage over standard preventive therapy for persons with inactive pulmonary T

127 th Crotalus atrox venom (Cv-PC) as potential preventive therapy for reducing perioperative hemorrhage

128 George Comstock's work on preventive therapy for TB demonstrated the use of epidem

129 omprehensive control strategies that combine preventive therapy for the most high-risk populations an

130 make individual patient decisions concerning preventive therapy for tuberculosis.

131 es of tuberculosis; 37 were in the isoniazid preventive therapy group (2.3 per 100 person-years, 95%

132 rical tuberculosis therapy) or the isoniazid preventive therapy group (antiretroviral therapy and iso

133 ns in 19 of 662 individuals in the isoniazid preventive therapy group and ten of the 667 individuals

134 uberculosis therapy and 426 to the isoniazid preventive therapy group.

135 p and 97 (23%) participants in the isoniazid preventive therapy group.

136 p and 46 (11%) participants in the isoniazid preventive therapy group.

137 No safe and effective preventive therapy has been identified, but promising ne

138 P panel can refine risk in women who receive preventive therapy has not been directly assessed previo

139 Preventive therapies have been demonstrated to improve o

140 This has become of paramount importance, as preventive therapies have evolved for recurrent attacks

141 emature death may assist in the targeting of preventive therapies in order to improve overall health.

142 ortality risk are needed to optimally target preventive therapies in patients with coronary artery di

143 ide (CGRP) pathway is a promising target for preventive therapies in patients with migraine.

144 dies will aid in design and effective use of preventive therapies in the very low birth weight infant

145 duce early mortality compared with isoniazid preventive therapy in high-burden settings.

146 d preventive therapy (IPT) is recommended as preventive therapy in HIV-infected persons.

147 MTB) infection and indications for isoniazid preventive therapy in HIV-infected persons.

148 mpirical tuberculosis therapy with isoniazid preventive therapy in HIV-positive outpatients initiatin

149 ortality at 24 weeks compared with isoniazid preventive therapy in outpatient adults with advanced HI

150 tematic tuberculosis screening and isoniazid preventive therapy in outpatients with advanced HIV dise

151 Antimalarial intermittent preventive therapy in pregnancy (IPTp) and insecticide-t

152 monitoring the effectiveness of intermittent preventive therapy in pregnancy (IPTp) with SP is crucia

153 WHO recommends intermittent preventive therapy in pregnancy with sulfadoxine-pyrimet

154 Yet, SP is efficacious as intermittent preventive therapy in pregnant women (IPTp) and infants

155 ns for approaches to empirical treatment and preventive therapy in some regions of the world.

156 ses have called for the use of probiotics as preventive therapy in subsets of this population.

157 -reported symptoms on long-term adherence to preventive therapy in the United Kingdom sample of the I

158 generalists who would not recommend primary preventive therapy in these scenarios appeared to give m

159 urrent are promising candidates for an early preventive therapy in young phenotype-negative subjects

160 A total of 118 persons received preventive therapy, including 56 young children who were

161 rate of hepatotoxicity in persons receiving preventive therapy increased with increasing age (chi2 f

162 Preventive therapies initiated after myocardial infarcti

163 From the median time for preventive therapy initiation (50 days), fatal and nonfa

164 e I randomized controlled trial of isoniazid preventive therapy (IPT) before revaccination with bacil

165 rld Health Organization recommends isoniazid preventive therapy (IPT) for HIV-positive contacts and t

166 Isoniazid preventive therapy (IPT) for HIV-TB coinfected individua

167 Trials of isoniazid preventive therapy (IPT) for people living with HIV in s

168 Regimens for isoniazid-based preventive therapy (IPT) for tuberculosis (TB) in HIV-in

169 d contacts (<5 years) who received isoniazid preventive therapy (IPT) had developed disease compared

170 erculosis case finding or prior to isoniazid preventive therapy (IPT) in patients infected with human

171 duced a high rate of completion of isoniazid preventive therapy (IPT) in those persons after their di

172 Isoniazid preventive therapy (IPT) is recommended as preventive th

173 Isoniazid preventive therapy (IPT) was prescribed to <1% of ART en

174 ulin skin tests (TST) benefit from isoniazid preventive therapy (IPT) whereas those testing TST-negat

175 iretroviral therapy (ART), 6-month isoniazid preventive therapy (IPT), or both among HIV-infected adu

176 antiretroviral therapy (ART), and isoniazid preventive therapy (IPT).

177 as insecticide-treated nets and intermittent preventive therapy (IPT).

178 sulfadoxine-pyrimethamine (SP) intermittent-preventive-therapy (IPTp) for malaria in HIV-infected pr

179 Tuberculosis preventive therapy is a poorly used method that is essen

180 Preventive therapy is an important element of syphilis c

181 h by rupture for larger AAAs, no guidance or preventive therapy is currently available for the >90% o

182 n against tuberculosis provided by isoniazid preventive therapy is not known for human immunodeficien

183 These data indicate that INH preventive therapy is not routinely indicated in anergic

184 Preventive therapy is probably indicated in about a thir

185 Isoniazid preventive therapy is recommended in HIV-positive adults

186 Patients who adhere to preventive therapies may be more likely to engage in a b

187 scuss how risk factor modification and other preventive therapies may help curb the rising incidence

188 were randomly assigned to receive isoniazid preventive therapy (n=662) or placebo (n=667) between Ja

189 o 22.01; p = 0.009), self-reported isoniazid preventive therapy (odds ratio, 0.18; CI, 0.04 to 0.82;

190 Preventive therapy of sickle pain is best achieved with

191 We aimed to assess the effect of isoniazid preventive therapy on the risk of tuberculosis in people

192 d (1:1) patients to receive either isoniazid preventive therapy or a placebo for 12 months (could be

193 pregnant women living with HIV for isoniazid preventive therapy or for further investigation for tube

194 s could be due to the lack of cure following preventive therapy or reinfection with rapid progression

195 py naive individuals following completion of preventive therapy (or placebo) was fitted to posttherap

196 ce sustainable large scale implementation of preventive therapy programmes.

197 Preventive therapy programs among the general population

198 ity-based tuberculin screening and isoniazid preventive therapy project among high-risk inner-city re

199 his community-based tuberculin screening and preventive therapy project were the low proportion of in

200 Preventive therapy (PT) was prescribed for 324 (34%) and

201 als with skin test conversions who agreed to preventive therapy received either INH, rifampin, or a c

202 the tolerability and toxicity of a standard preventive therapy regimen given to children exposed to

203 This 3-drug preventive therapy regimen was well tolerated and few ch

204 community-based programs to be efficacious, preventive therapy regimens that are of shorter duration

205 e evaluated the safety and efficacy of three preventive-therapy regimens in a setting where exposure

206 FQN preventive therapy resulted in health system savings, lo

207 In our model, FQN preventive therapy resulted in substantial health system

208 Treatment with any rifampin-containing preventive therapy (rifampin or rifampin plus INH) was e

209 We assumed that without preventive therapy, seven cases of tuberculosis would ha

210 latent Mycobacterium tuberculosis infection (preventive therapy), shorten the time between disease on

211 e algorithm that predicts benefit, isoniazid preventive therapy should be recommended to all patients

212 Isoniazid preventive therapy significantly reduced tuberculosis ri

213 Co-trimoxazole preventive therapy started before or with ART, irrespect

214 anergic subjects in the placebo arms of the preventive therapy study underwent repeat skin testing a

215 ial to benefit from more intensive secondary preventive therapy such as treatment with vorapaxar.

216 Antimalarial intermittent preventive therapy (sulfadoxine-pyrimethamine) and insec

217 heart disease patients and discusses several preventive therapies that may reduce cardiovascular risk

218 e of invasive angiography and alterations in preventive therapies that were associated with a halving

219 ally despite the availability of life-saving preventive therapy, the implantable cardioverter defibri

220 screening ankle-brachial index benefit from preventive therapies to reduce cardiovascular risk is un

221 herent, are not sufficient to recommend mass preventive therapy to healthy women.

222 The provision of preventive therapy to vulnerable children following expo

223 the potential, especially with provision of preventive therapy, to augment a comprehensive package o

224 rgent need for improved detection, vaccines, preventive therapy, treatment, and support for affected

225 ected subjects screened for the tuberculosis preventive therapy trial compared with 10% of 682 HIV-no

226 HIV-infected persons being screened for a TB preventive therapy trial in Uganda with an initial purif

227 lts followed prospectively in a tuberculosis preventive therapy trial in Uganda.

228 had completed at least 5 months of isoniazid preventive therapy, unless they had completed treatment

229 luding 56 young children who were prescribed preventive therapy until skin tests performed at least 1

230 Preventive therapy using imatinib or nilotinib inhibited

231 hout cardiovascular disease, use of multiple preventive therapies was associated with 65% lower all-c

232 , TST-positive patients who did not take INH preventive therapy was 5.0 per 100 person-yr, compared w

233 d hepatotoxicity during clinically monitored preventive therapy was lower than has been reported prev

234 berculosis in the three groups that received preventive therapy was lower than the rate in the placeb

235 ted no evidence that the effect of isoniazid preventive therapy was restricted to patients who were p

236 terized reminders on the rates at which four preventive therapies were ordered for inpatients.

237 Gender disparities in recommendations for preventive therapy were explained largely by the lower p

238 below 200/microl and who were not receiving preventive therapy were nine times more likely to develo

239 Data on type and length of preventive therapy were obtained from the Tuberculosis C

240 depending on the severity of the headache), preventive therapy (when the headaches are frequent or c

241 cs will probably best serve as adjunctive or preventive therapies, which suggests that conventional a

242 An opportunity exists for preventive therapy, which should improve the reproductiv

243 Antenatal intermittent preventive therapy with 2 doses of sulfadoxine-pyrimetha

244 nt women in sub-Saharan Africa, intermittent preventive therapy with 3 or more doses of sulfadoxine-p

245 Providing preventive therapy with contact tracing nearly doubled t

246 Preventive therapy with lamivudine for patients who test

247 Preventive therapy with LDE223 almost completely impeded

248 Where the risk of reinfection is lower, preventive therapy with more curative drugs should be pr

249 xacin as optimal therapy for pouchitis, when preventive therapy with probiotics is not successful.

250 All 157 students were prescribed preventive therapy with rifampin (10 mg/kg up to 600 mg

251 In conclusion, preventive therapy with rifampin was well tolerated and

252 require more frequent doses of intermittent preventive therapy with SP than do HIV-uninfected (HIV(-

253 Intermittent preventive therapy with sulfadoxine-pyrimethamine to con